Shares of Apricus Biosciences Inc (NASDAQ:APRI) gapped down before the market opened on Monday . The stock had previously closed at $5.31, but opened at $3.19. Apricus Biosciences shares last traded at $1.04, with a volume of 18851900 shares changing hands.
A number of analysts have recently commented on the stock. HC Wainwright cut shares of Apricus Biosciences from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a report on Friday. Zacks Investment Research cut shares of Apricus Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. Finally, ValuEngine upgraded shares of Apricus Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
The company has a market capitalization of $15.82, a price-to-earnings ratio of 1.79 and a beta of 0.38.
An institutional investor recently bought a new position in Apricus Biosciences stock. Healthcare Value Capital LLC bought a new stake in shares of Apricus Biosciences Inc (NASDAQ:APRI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 100,000 shares of the company’s stock, valued at approximately $184,000. Apricus Biosciences makes up 0.6% of Healthcare Value Capital LLC’s holdings, making the stock its 8th largest position. Healthcare Value Capital LLC owned 0.66% of Apricus Biosciences as of its most recent SEC filing. Institutional investors own 24.39% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Apricus Biosciences (APRI) Shares Gap Down to $3.19” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/19/apricus-biosciences-apri-shares-gap-down-to-3-19.html.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.